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ABSTRACT
Objective To characterise the impact of dactylitis in 
disease- modifying antirheumatic drug (DMARD)- naive 
early psoriatic arthritis (PsA).
Methods Patients with early PsA meeting the 
classification criteria for PsA (CASPAR) were recruited. 
Clinical outcomes were recorded, and ultrasonography 
was conducted to assess grey scale (GS) and power 
Doppler (PD) synovitis, periarticular cortical bone 
erosions and enthesitis. The cohort was dichotomised by 
the presence or absence of dactylitis.
Results Of 177 patients with PsA, those with dactylitis 
(dactylitic PsA (81/177, 46%)) had higher tender joint 
count (p<0.01), swollen joint count (SJC) (p<0.001) and 
C reactive protein (CRP) (p<0.01) than non- dactylitic 
PsA. Dactylitis was more prevalent in toes (146/214 
(68.2%)) than fingers (68/214 (31.8%)); ’hot’ dactylitis 
was more prevalent than ’cold’ (83.6% vs 16.4%). 
Ultrasound (US) synovitis and erosions were significantly 
more prevalent in dactylitic PsA (p<0.001 and p<0.001, 
respectively). Exclusion of dactylitis in dactylitic PsA 
confirmed significantly greater SJC (3 vs 1, p=0.002), US 
synovitis (GS ≥2: 20.6% vs 16.1%, p<0.001, or PD ≥1: 
5.1% vs 3.3%, p<0.001) and erosions (1.1% vs 0.5% 
joints, p=0.008; 26.1% vs 12.8% patients, p=0.035%) 
than non- dactylitic PsA. Synovitis (GS ≥2 and/or 
PD ≥1) occurred in 53.7% of dactylitis. No substantial 
differences were observed for US enthesitis.
Conclusion Dactylitis signifies a more severe disease 
phenotype independently associated with an increased 
disease burden with greater SJC, CRP, US- detected 
synovitis and bone erosions in DMARD- naive early 
PsA and may be a useful discriminator for early risk 
stratification.
INTRODUCTION
Dactylitis is defined as diffuse swelling of a finger 
or toe and represents a specific lesion typically 
associated with psoriatic arthritis (PsA). The prev-
alence of dactylitis in PsA has been estimated at 
33%–55%, with approximately 70% occurring 
at presentation.1 Dactylitis is the epitome of PsA 
pathophysiology, encompassing multiple under-
lying pathologies including inflammation to joints 
(synovitis) and tendons/ligaments (enthesitis). 
Flexor tenosynovitis, surrounding diffuse periten-
dinous inflammation and soft tissue oedema, are 
typically responsible for the ‘sausage digit’ appear-
ance.2 Importantly, synovitis and bone erosion can 
develop, adding to further structural and functional 
impairments.3 Bone marrow oedema and ligamen-
tous enthesitis have also been demonstrated using 
high- resolution MRI.4 At the bedside, the accu-
racy of ultrasound (US) for detecting inflammatory 
arthritis in PsA is regarded as comparable to MRI, 
with studies suggesting US may be superior for the 
assessment of synovitis.5
Key messages
What is already known about this subject?
 ► Dactylitis is a typical lesion in psoriatic arthritis 
(PsA) and is associated with radiographic 
progression in chronic disease.
 ► In early PsA, dactylitis is a common finding, 
but the associated impact of this lesion on the 
disease burden is unknown.
What does this study add?
 ► This study demonstrates that disease- modifying 
antirheumatic drug (DMARD)- naive patients 
with early PsA with dactylitis (dactylitic PsA) 
have a greater burden of disease than patients 
with PsA without dactylitis (non- dactylitic 
PsA), which was confirmed independently (ie, 
when dactylitis was excluded) demonstrating 
greater swollen joint count, C reactive protein, 
ultrasound (US) synovitis and US erosions.
 ► Our data confirm that dactylitis is a clinical 
marker of a more severe phenotype in DMARD- 
naive early PsA.
How might this impact on clinical practice or 
future developments?
 ► In patients with early PsA, the presence of 
dactylitis identifies a more severe disease 
phenotype and may be an important 
discriminator for risk stratification in early 
arthritis clinics and clinical research trials.
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The presence or history of dactylitis adds high sensitivity and 
specificity towards classifying PsA (CASPAR criteria).6 Further, 
dactylitis is associated with greater radiographic damage in 
chronic established PsA.7 However, to our knowledge, direct 
evaluation of the impact of dactylitis on overall disease pheno-
type and severity in early, untreated PsA has not been charac-
terised. The objective of this study was to determine the impact 
of dactylitis on clinical phenotype, US synovitis and erosion in 
disease- modifying antirheumatic drug (DMARD)- naive early 
PsA.
METHODS
Patients, clinical details and examination
In total, 177 DMARD- naive patients with early PsA meeting 
CASPAR criteria were recruited into the Leeds Spondyloar-
thropathy Register for Research and Observation for baseline 
cross- sectional analysis.6 Clinical examination included tender 
joint count (TJC) (78) and swollen joint count (SJC) (76). The 
early PsA cohort was dichotomised by the presence or absence 
of dactylitis at baseline (PsA with dactylitis (dactylitic PsA) or 
PsA without dactylitis (non- dactylitic PsA)). Dactylitis was 
recorded per digit via the dichotomous (Clegg et al) method 
including tender (‘hot’) or non- tender (‘cold’) status.8 9 Clinical 
enthesitis was measured by the Maastricht Ankylosing Spondy-
litis Enthesitis Score (MASES) to include peripheral and axial 
entheses.
US examination
Experienced ultrasonographers blinded to clinical details (four 
operators with over 5 years’ experience) scanned 50 joints per 
patient using the GE Logiq E9 machine with matrix linear (ML) 
15–6 MHz or small- footprint linear array 18–8 MHz transducer 
and had regular training and calibration on the US examination 
protocol and quality of sonographic assessment throughout the 
study period, conducted every 6 months to maintain high consis-
tency for US assessment, image interpretation and scoring.
Synovitis
Synovitis was graded by semiquantitative scores (0–3) and 
defined as grey scale (GS) ≥2)  or abnormal power Doppler (PD) 
signal (PD ≥1), and GS  of ≤1 was determined as non- significant 
as it occurs frequently in healthy individuals.10
Wrists (radiocarpal, intercarpal and ulnar carpal recesses), 
metacarpophalangeal (MCP) joints 1–5, proximal interphalan-
geal (PIP) joints 1–5, distal interphalangeal joints 2–5, elbows, 
knees (suprapatellar, medial parapatellar and lateral parapatellar 
recesses), ankles (tibiotalar joint), subtalar joints, talonavicular 
joints and metatarsophalangeal (MTP) joints 1–5 were scanned 
in longitudinal and transverse planes (online supplemental table 
S1A).
Erosions
Erosions were determined by periarticular cortical bone discon-
tinuity present in two perpendicular planes (longitudinal and 
transverse), with MTP1 excluded as it is a frequent site of 
osteoarthritis.
Enthesitis
Enthesitis was determined by the Outcome MEasures in Rheu-
matology (OMERACT)- defined elementary lesions and modi-
fied Glasgow Ultrasound Enthesitis Severity Score (GUESS), 
calculated per patient based on all the enthesitis sites and 
domains (except bursitis at the quadriceps tendon insertion—not 
recorded in the study protocol).11 12 The US data recorded for 
entheses are shown in online supplemental table S1 (B).
Statistical analysis
Statistical tests were two- tailed, statistical significance prespeci-
fied at 5% (p<0.05) with 95% CIs. Differences between mean, 
medians and proportions were calculated using Student’s t- test, 
quantile regression (continuous variables), χ2 test (binary vari-
ables) and Kruskal- Wallis (categorical variables) via Stata V.16.1.
RESULTS
Clinical characteristics
Dactylitic PsA versus non-dactylitic PsA
Dactylitic PsA occurred in 81/177 (46%) patients vs non- 
dactylitic PsA in 96/177 (54%) patients. Mean ages were similar; 
43.7 and 44.4 years, respectively. More patients in the dactylitic 
group had a symptom duration of <24 months (68/81 (84%) 
vs 64/96 (66.7%), p=0.008). The median TJCs and SJC were 
significantly greater in patients with dactylitic PsA compared 
with patients without dactylitic PsA (TJC: 9 vs 4, p<0.01; SJC 7 
vs 1, p<0.001), with polyarthritis being the predominant pheno-
type in dactylitic PsA (65.4%, p<0.01), while oligoarthritis was 
dominant in non- dactylitic PsA (86.5%, p<0.001). Excluding 
dactylitis affected digits, dactylitic PsA remained predominantly 
polyarticular (51/81 patients, 62.9%), and the SJC (but not the 
TJC) still significantly greater (total SJC: 326 joints (81 patients) 
vs 209 joints (96 patients), median 3 vs 1, p=0.002).
Clinical enthesitis was more prevalent in patients with 
dactylitic PsA (42/81 (51.9%) vs 34/96 (35.4%); p=0.027), with 
greater median MASES (1.0 (0.0–2.0) vs 0.0 (0.0–2.0); p<0.01). 
The prevalence of nail dystrophy did not differ between groups, 
however the median modified nail psoriasis severity index 
(mNAPSI) was greater in non- dactylitic PsA (2.0 (0.0–7.5) vs 0.0 
(0.0–8.0); p<0.05).
Elevated C reactive protein (CRP >10 mg/L) occurred more 
frequently in dactylitic versus non- dactylic patients (44% vs 25% 
(p=0.006)) including with a greater median CRP and erythro-
cyte sedimentation rate (ESR; mm/hr) (CRP: 8.1 vs 5.0 (p<0.01), 
ESR: 16.5 vs 11 (p<0.05)). Disease Activity in Psoriatic Arthritis 
(DAPSA) scores were greater in dactylitic PsA but not significant 
(median 24.4 vs 20.8, p=0.07). No significant differences were 
observed in PsAQoL, HAQ, and DLQI. Comparison of patient 
characteristics between groups are shown in table 1.
Characteristics of dactylitis
Of 81/177 (45.8%) patients with dactylitic PsA, dactylitis 
affected 214 digits, predominantly with multiple digit involve-
ment (>1) in 51/81 (63%) patients (median digits: 2 (IQR 1–3)) 
and was distributed asymmetrically (52/81 (64%) patients). 
Hands were affected in 23/81 (28.4%) patients, feet in 40/81 
(49.4%), and both in 18/81 (22.2%). Dactylitis was more preva-
lent in toes (146/214, 68.2%) than fingers (68/214, 31.8%) with 
the majority of digits classified as hot dactylitis (179/214 digits, 
83.6%) (cold dactylitis (35/214, 16.4%)). The second finger 
(23/179, 12.8%) and fourth toe (40/179; 22.3%) were most 
frequently affected by hot dactylitis, and the third finger (2/35; 
5.7%) and fourth toe (10/35; 28.6%) by cold dactylitis (online 
supplemental figure S1A).
US synovitis
In total, 155/177 (87.5%) patients with PsA underwent ultra-
sonography (6143 joints): 69/155 (44.5%) patients with 
dactylitic PsA and 86/155 (55.5%) without dactylitic PsA 
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(online supplemental figure S1B). US synovitis was significantly 
more prevalent in dactylitic PsA (GS ≥2: 23.6% vs 16.1% 
joints (p<0.001); PD ≥1: 7.3% vs 3.3% joints (p<0.001); 
GS ≥2+PD ≥1: 6.3% vs 2.6% joints (p<0.001)) as outlined in 
table 2A. GS ≥2 synovitis was most frequently observed at MCP 
2–5, PIP1–3, MTP2–5, and PD ≥1 synovitis at MCP 2 and MTP 
4–5. On exclusion of digits affected by dactylitis, US synovitis 
remained significantly more prevalent in patients with dactylitic 
PsA (GS ≥2: 21.3% vs 16.1% joints (p<0.001); PD ≥1: 5% vs 
3.3% joints (p<0.001); GS ≥2+PD ≥1: 4.1% vs 2.6% joints 
(p<0.003); table 2B). Further subgroup analyses stratified for 
phenotype (defined by SJC ≥5 as polyarticular) confirmed 
greater GS ≥2 and PD ≥1 synovitis, respectively, for polyartic-
ular subsets in dactylitic PsA (p<0.001), including greater GS ≥2 
synovitis when dactylitis was excluded (p=0.01) (online supple-
mental table S2). Application of the second definition inclusive of 
tender joints (tender and/or swollen joints<5 as oligoarticular) 
indicated significantly greater GS  of ≥2 and PD  of ≥1 synovitis, 
respectively, independent of phenotype in dactylitic PsA. Exclu-
sion of dactylitis from dactylitic PsA also confirmed greater GS  of 
≥2 synovitis in oligoarticular and polyarticular subsets indepen-
dent of dactylitis affected joints (online supplemental table S3).
US erosions
Periarticular cortical bone erosions were identified in a signifi-
cantly greater proportion of patients with dactylitic PsA, 
compared with those without dactylitis (20/69 (29.0%) vs 
11/86 (12.8%), p=0.012). There was also a significant differ-
ence in the total number of erosions detected in dactylitic versus 
patients without dactylitic PsA (33/2557 joints vs 15/3206 joints, 
p<0.001; table 2A). The anatomical sites for joints most prone 
to erosive damage were MCP2 (9/33 (27.3%)) and MTP5 (11/33 
(33.3%)).





(81/177 (45.8%)) Difference/p value
Clinical
  Age (years), mean (SD) 44.4 (12.8) 43.7 (13.3) 0.7 (−3.2 to 4.5)
  Male 38 (39.6%) 42 (51.9%) p=0.10
  Symptom duration (months), median (IQR) 18.0 (10.5–36.0) 12.0 (6.0–24.0) −6.0 (−13.1 to 1.1)
  Duration from diagnosis (months), median (IQR) 1.1 (0–2.7) 1.2 (0.3–4.6) 0.03 (−0.9 to 1.0)
  Symptoms <24 months, patients (%) 64/96 (66.7) 68/81 (84.0) p=0.008
  Early morning stiffness (min), median (IQR) 50.0 (15.0–90.0) 60.0 (15.0–180.0) 0 (−24.1 to 24.1)
  TJC (78), median (IQR) 4.0 (1.0–10) 9.0 (5.0–19.0) 5.0 (2.0 to 8.0)**
  SJC (76), median (IQR) 1.0 (0.0–3.0) 7.0 (4.0–13.0) 6.0 (4.3 to 7.6)***
  TJC (78) median (IQR) (excluding dactylitis) 4.0 (1.0–10.0) 5.0 (2.0–11.0) 1.0 (−1.4 to 3.4)
  SJC (76) median (IQR) (excluding dactylitis) 1.0 (0.0–3.0) 3.0 (1.0–6.0) 2.0 (0.8 to 3.3)**
  Current psoriasis 96/96 (100.0%) 74/81 (91.4%) p=0.003**
  Family history of psoriasis 52/94 (55.3%) 49/78 (62.8%) p=0.32
  PASI, median (IQR) 2.9 (0.8–4.9) 1.9 (0.4–4.2) −1.2 (−2.4 to 0.0)
  Psoriatic nail dystrophy 49/96 (51.0%) 44/81 (54.3%) p=0.66
  mNAPSI, median (IQR) 2.0 (0.0–7.5) 0.0 (0.0–8.0) −2.0 (−3.7 to −27.9)*
  Clinical Enthesitis 34/96 (35.4%) 42/81 (51.9%) p=0.027*
  MASES score, median (IQR) 0.0 (0.0–2.0) 1.0 (0.0–2.0) 1.0 (0.4 to 1.6)**
  BMI, median (IQR) 28.2 (24.0–32.1) 28.6 (25.0–31.5) 0.3 (−1.7 to 2.4)
  Smoking (current) 19 (19.8%) 9 (11.1%) p=0.11
Disease phenotype
  Oligoarthritis (defined by SJC <5) 83/96 (86.5%) 28/81 (34.6%) p<0.001***
  Oligoarthritis (defined by TJC and/or SJC <5) 48/96 (50%) 29/81 (35.8%) p=0.058
  DIP joint disease 7/93 (7.5%) 13/77 (16.9%) p=0.058
  Axial disease 17/94 (18.1%) 9/78 (11.5%) p=0.23
  Arthritis mutilans 0 0 0
Laboratory markers
  CRP (mg/L), median (IQR) 5.0 (5.0–9.3) 8.1 (5.0–18.4) 3.1 (0.9–5.3)**
  Elevated CRP (>10 mg/L) 24/96 (25.0%) 36/81 (44.4%) p=0.006**
  ESR, median (IQR) 11.0 (5.0–25.0) 16.5 (7.0–27.0) 7.0 (0.4–13.6)*
Composite outcomes
  DAPSA score, median (IQR) 20.8 (12.6, 30.5) 24.4 (14.9, 36.5) p=0.07
Patient- reported outcomes (PROs)
  PsAQoL, median (IQR) 6.0 (0.0–13.0) 6.0 (2.0–12.0) 0.0 (−4.1 to 4.1)
  DLQI, median (IQR) 3.0 (1.0–9.0) 2.0 (1.0–6.0) −1.0 (−3.3 to 1.3)
  HAQ, median (IQR) 0.75 (0.25–1.50) 0.75 (0.38–1.38) 0.125 (−0.23 to 0.48)
*p<0.05, **p<0.01, ***p<0.001.
BMI, body mass index; CRP, C reactive protein; DAPSA, Disease Activity in Psoriatic Arthritis; DIP, distal interphalangeal; DLQI, Dermatology Quality of Life Index; ESR, erythrocyte 
sedimentation rate; HAQ, Health Assessment Questionnaire Disability Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; mNAPSI, Modified Nail Psoriasis Severity 
Index; PASI, Psoriasis Area Severity Index; ; PsA, psoriatic arthritis; PsAQoL, PsA quality of life; SJC, swollen joinr count; TJC, tender joint count.  on D
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On exclusion of dactylitic digits, US erosions were more 
frequent in dactylitic PsA than non- dactylitic PsA (24/2315 
(1.1%) vs 15/3206 (0.5%) joints, p=0.008). The proportion 
of patients with US erosions (US erosion- positive patients) was 
greater for dactylitic PsA (18/69 (26.1%) vs 11/86 (12.8%) 
patients, p=0.035). Total erosion scores at the patient level were 
also higher in dactylitic PsA (p=0.016), including when dactylitis 
was excluded (p=0.048), as shown in table 2B. Subgroup anal-
yses confirmed greater total US- detected erosions in polyarticular 
stratified subsets regardless of the phenotype definition applied 
and on excluding dactylitis affected joints (online supplemental 
table S2 and S3). The US appearances of erosions detected in the 
dactylitic PsA group are illustrated in figure 1B,D.
US in dactylitis
In digits affected by dactylitis, US synovitis (GS ≥2) was prev-
alent in 137/255 (53.7%) joints. A higher prevalence of US 
synovitis was observed in joints affected by hot dactylitis versus 
those with the cold type (129/227 (56.8%) vs 8/28 (28.6%) 
joints, p=0.0047). US PD synovitis (PD ≥1 regardless of GS 
grade) was present in 72/255 (28.2%) of the total joints clini-
cally affected by dactylitis and was more prevalent in hot type 
(hot: 69/227 (30.4%) and cold: 3/28 (10.7%) joints, p=0.0289). 
In hot dactylitis, erosions occurred in 9/227 (2.6%) of affected 
joints (4/69 (6%) patients) and none in cold dactylitis (0/28) 
(p=0.388). Figure 1 illustrates synovitis at MTP5 (figure 1A) and 
shows soft tissue oedema and flexor tenosynovitis (figure 1E).
US enthesitis
Of 1534 entheses examined by US, modified GUESS scores indi-
cated no significant differences between patients with dactylitic 
PsA and patients without dactylitic PsA (median 3 (IQR 2–6) vs 
median 4 (IQR 1–6), p=0.91). There were no relevant differ-
ences between groups on analysis of OMERACT elementary 
lesions.
DISCUSSION
This is the first study, to our knowledge, to evaluate the overall 
clinical and US disease burden in a DMARD- naive early PsA 
cohort based on the presence/absence of dactylitis. These 
study results confirmed a greater burden of disease in PsA with 
dactylitis. Moreover, patients with dactylitic PsA had greater 
SJC, CRP, prevalence of US synovitis and erosive damage inde-
pendently (ie, on exclusion of digits affected by dactylitis) 
compared with non- dactylitic PsA. These results therefore 
provide an insight into the significance of dactylitis in early PsA, 
demonstrating that it is an indicator of a more severe phenotype. 
Indeed, more aggressive disease accounted for an earlier diag-
nosis of patients with dactylitic PsA who presented with shorter 
disease duration. Further analyses to include history of dactylitis 
and exclude patients with a symptom duration of >24 months, 
respectively, did not change results confirming the increased 
burden of disease in the dactylitic group (online supplemental 
table S4 and S5).
Previous studies in established PsA have shown that digits 
affected by dactylitis are associated with significant patholog-
ical findings. Brockbank et al first reported that radiographic 
damage occurred frequently in hot dactylitis with an average PsA 
cohort disease duration of 8 years.7 Healy et al reported a high 
prevalence of synovitis in hot dactylitis present on MRI in 69%, 
closely matching the prevalence of US detected synovitis in our 
study (56.8%), confirming that synovitis is present in the majority 
of dactylitis in early PsA.13 Moreover, in our early PsA study, 
the greater prevalence of US synovitis and erosions in patients 
with dactylitic PsA (vs non- dactylitic PsA), even when excluding 
the dactylitis digits, has to our knowledge not previously been 
shown and reflects an increased burden of disease. Further, this 
was reflected by CRP, also a marker of disease activity which 
was elevated (>10 mg/L) more often in patients with dactylitic 
PsA (44.4% vs 25%, p=0.006) and with higher median values. 
This is a relevant observation, since elevated baseline CRP is 
associated with poor radiographic outcomes.14 Additionally, 
radiographic joint destruction is reportedly predicted by the 
development of dactylitis in men from longitudinal PsA cohort 
data.15 Despite the differences found for clinical enthesitis, a 
possible limitation of our study was the inability to show mean-
ingful differences in US enthesopathy possibly related to the 
outcomes used or the known clinical and US mismatch shown 
in other stuides.16 However, our results do provide new data, 
including for US synovitis and erosion, showing that there is a 
difference in the burden of disease between patients with early 
PsA with and without dactylitis.
Table 2 Ultrasound synovitis and bone erosions in non- dactylitic versus dactylitic PsA: (A) including dactylitis affected digits and (B) excluding 
dactylitis affected digits




(69/155 (44.5%) patients) Difference
Total GS ≥2 (joints) 551/3422 (16.1%) 642/2721 (23.6%) p<0.001
Total PD ≥1 (joints) 114/3422 (3.3%) 198/2721 (7.3%) p<0.001
Total GS ≥2+PD >1 (joints) 89/3422 (2.6%) 171/2721 (6.3%) p<0.001
Total US erosions (joints) 15/3206 (0.5%) 33/2557 (1.3%) p<0.001
Total erosion score (patient level) Mean 0.28 (SD 0.87), median 0 (0–0) Mean 0.72 (SD 1.63), median 0 (0–1) p=0.016
Total US erosive patients 11/86 (12.8%) 20/69 (29.0%) p=0.012
(B) US synovitis and erosions
Non- dactylitic PsA
(86/155 (55.5%)) (same as A)
Dactylitic PsA
(69/155 (44.5%)) (dactylitis excluded) Difference
Total GS ≥2 (joints) 551/3422 (16.1%) 507/2466 (20.6%) p<0.001
Total PD ≥1 (joints) 114/3422 (3.3%) 126/2466 (5.1%) p<0.001
Total GS ≥2+PD >1 (joints) 89/3422 (2.6%) 101/2466 (4.1%) p=0.003
Total US erosions (joints) 15/3206 (0.5%) 24/2315 (1.1%) p=0.008
Total erosion score (patient level) Mean 0.28 (SD 0.87), median 0 (0–0) Mean 0.58 (SD 1.52), median 0 (0–1) p=0.048
Total US erosive patients 11/86 (12.8%) 18/69 (26.1%) p=0.035
GS, grey scale; PD, power Doppler; PsA, psoriatic arthritis.
 on D
ecem









is: first published as 10.1136/annrheum






5Dubash S, et al. Ann Rheum Dis 2021;0:1–6. doi:10.1136/annrheumdis-2021-220964
Psoriatic arthritis
Tailoring therapy specific to PsA phenotypes is increasingly 
pertinent to avoid biologic disease- modifying antirheumatic 
drug (bDMARD) failure, especially given the diverse mode 
of action therapies available. Moreover, superior treatment 
responses have been shown for dactylitis with bDMARDs over 
conventional synthetic DMARDs, including first- line combi-
nation therapy.17 18 Our study findings can facilitate early risk 
stratification to optimise treatment outcomes, coherent with the 
European Alliance of Associations for Rheumatology (EULAR) 
recommendations that regard dactylitis as a poor prognostic 
factor in early PsA and advocate rapid initiation of DMARDs.19 
Overall, these data may further inform management strategies, 
including clinical trials for targeted therapy to understand differ-
ential responses within PsA phenotypes.
CONCLUSIONS
The presence of dactylitis is independently associated with 
an increased burden of disease with greater SJC, CRP, US- de-
tected synovitis and erosive bone damage in DMARD- naive 
early PsA. Dactylitis should therefore be considered a clinical 
marker for a more severe phenotype in early PsA and may be an 
important discriminator for risk stratification in early interven-
tion strategies.
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Figure 1 Characteristic ultrasound pathologies in early dactylitic patients with PsA. (A) Longitudinal view through the fifth metatarsophalangeal 
joint illustrating synovitis within a dactylitic toe. There is grey scale synovitis (grade 3) with effusion (*) and abnormal power Doppler signal (grade 
2, right image) consistent with ‘active’ synovitis. (B) Periarticular cortical bone irregularity at the second MCP joint confirmed in the longitudinal 
(left) and transverse planes, respectively (right), confirming erosion. A common site of erosion in PsA and in dactylitis. (C) Longitudinal view at the 
MCP joint displaying power Doppler signal above the extensor tendon (PTI). (D) Image in the transverse plane showing the fifth metatarsal head, the 
most frequent site of erosion in feet, demonstrating periarticular bone irregularity (arrow). Bone irregularity was confirmed further in the longitudinal 
plane to signify erosion. There is also surrounding grey scale synovial hypertrophy (grade 2). (E) Transverse view of volar aspect of dactylitic third 
toe showing diffuse soft tissue oedema (large arrow) and flexor tenosynovitis (small arrow). MCP, metacarpophalangeal; MC, metacarpal head; MT, 
metatarsal head; P, phalanx; PsA, psoriatic arthritis; PTI, peritendon inflammation.
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Supplementary table S1. The ultrasound assessment of joints (A) and entheses 
(B). The source data collected on imaging is shown in the tables below: 
 
Table A: Ultrasound imaging data collection for synovitis:  
Right Left 












Wrist    Wrist    
MCP1    MCP1    
MCP2    MCP2    
MCP3    MCP3    
MCP4    MCP4    
MCP5    MCP5    
        
PIP1    PIP1    
PIP2    PIP2    
PIP3    PIP3    
PIP4    PIP4    
PIP5    PIP5    
        
DIP2    DIP2    
DIP3    DIP3    
DIP4    DIP4    
DIP5    DIP5    
        
Elbow    Elbow    
Knee    Knee    
Ankle    Ankle    
TNJ    TNJ    
STJ    STJ    
        
MTP1    MTP1    
MTP 2    MTP 2    
MTP 3    MTP 3    
MTP 4    MTP 4    
MTP 5    MTP 5    
 
GS: grey scale; PD: power Doppler; DIP: distal interphalangeal joint; PIP: proximal 
interphalangeal joint; MCP: metacarpophalangeal joint; MTP: metatarsophalangeal joint; TNJ: 
talonavicular joint; STJ: subtalar joint. Semiquantitative scores (0-3) were recorded for the 
grading of GS, PD, erosion. 
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Table B: Ultrasound imaging data collection for enthesitis  
 AT PF DPT PPT QT 
Right      
Enthesis thickness (mm)      
Thickening (0-1)      
Hypoechogenicity (0-1)      
PD (0-1)      
Calcifications (0-1)      
Enthesophytes (0-1)      
Erosions (0-1)      
Bursitis (0-1)      
Left      
Enthesis thickness (mm)      
Thickening (0-1)      
Hypoechogenicity (0-1)      
PD (0-1)      
Calcifications (0-1)      
Enthesophytes (0-1)      
Erosions (0-1)      
Bursitis (0-1)      
 
AT: Achilles tendon enthesis; PF: plantar fascia; DPT: distal patellar tendon insertion; PPT: 
proximal patellar tendon insertion, QT: quadriceps tendon insertion. Reference values for 
enthesis thickening: AT≤ 5.29, PF: ≤ 4.4 mm; DPT: ≤ 4 mm; PPT: ≤ 4 mm; QT: ≤ 6.1 mm. 
Binary grading (0=absent; 1=present) was recorded for thickening, hypoechogenicity, 
power Doppler (PD), calcifications, enthesophytes, erosions, bursitis. 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis
 doi: 10.1136/annrheumdis-2021-220964–6.:10 2021;Ann Rheum Dis, et al. Dubash S
3 
 
Supplementary tables S2 a) Oligoarticular, b) Polyarticular:  
Subgroup analyses stratified by phenotype (polyarticular defined by SJC³5) for 
clinical characteristics (A), ultrasound synovitis and erosion outcomes with dactylitis 
digits included and excluded (B and C respectively) for dactylitic versus non-dactylitic 
PsA.  
 
S2 a) Oligoarticular subset 
 








Difference/ p value 
Clinical 
Age, mean (SD), years 43.7 (12.5) 42.9 (10.8) 0.8 (-4.5 to 6.0) 
Male 32 (39%) 12 (43%) p=0.69 
Symptom duration, median (IQR), 
months 
18.0 (8.0, 36.0) 14.5 (7.5, 24.0) -1.0 (-10.4 to 8.4) 
Duration from diagnosis, median 
(IQR), months 
1.0 (0.0, 2.6) 1.1 (0.0, 3.2) 0.16 (-1.1 to 1.4) 
Early morning stiffness median 
(IQR), minutes 
30.0 (10.0, 60.0) 60.0 (10.0, 120.0) 30 (-2.9 to 62.9) 
TJC (78), median (IQR) 4.0 (1.0, 9.0) 3.5 (2.0, 9.0) 0.0 (-2.7 to 2.7) 
SJC (76), median (IQR) 1.0 (0.0, 2.0) 2.0 (1.0, 3.0) 1.0 (0.2 to 1.8)* 
TJC (78) median (IQR) (excluding 
dactylitis) 
4.0 (1.0, 9.0) 2.0 (1.0-6.0) -2.0 (-4.7 to 0.7) 
SJC (76) median (IQR) (excluding 
dactylitis) 
1.0 (0.0, 2.0) 0.5 (0.0-1.0) 0.0 (-0.9 to 0.9) 
Current Psoriasis 83 (100%) 25 (89.3%) p=0.003* 
Family history of Psoriasis 42 (52%) 18 (69%) p=0.12 
PASI, median (IQR) 3.0 (0.7, 4.9) 1.0 (0.0, 3.0) -1.8 (-4.4 to -0.24)* 
Psoriatic Nail dystrophy 46 (55%) 13 (46%) p=0.41 
mNAPSI, median (IQR) 2.0 (0.0, 9.0) 0.0 (0.0, 4.0) -2.0 (-4.5 to 0.54) 
Clinical Enthesitis 33 (40%) 15 (54%) p=0.20 
MASES, median (IQR) 0.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (-0.07 to 2.07) 
BMI, median (IQR) 28.0 (24.0, 33.1) 27.1 (22.6, 28.8) -0.9 (-4.2 to 2.4) 
Smoking (current) 17 (20%) 5 (18%) p=0.59 
Disease phenotype 
Predominant DIP joint disease 5/80 (6.3%) 3/28(10.7%) p=0.44 
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Difference/ p value 
Axial disease 16/81 (19.8%) 2/28 (7.1%) p=0.12 
Arthritis Mutilans 0 0 0 
Laboratory markers 
CRP (mg/L), median (IQR) 5.0 (5.0, 8.8) 5.0 (5.0, 10.8) 0 (-1 to 1) 
Elevated (>10) 19 (22.9%) 8 (28.6 %) p=0.54 
ESR, median (IQR) 13.0 (6.0, 30.0) 13.0 (5.0, 25.0) 0 (-9.2 to 9.2) 
Patient Reported Outcomes (PROs) 
PsAQoL, median (IQR) 6.0 (0.0, 14.0) 3.0 (1.0, 7.0) -3.0 (-8.2 to 2.2) 
DLQI, median (IQR) 3.0 (1.0, 9.0) 2.0 (1.0, 6.0) -1.0 (-4.3 to 2.3) 
HAQ, median (IQR) 0.6 (0.1, 1.5) 0.4 (0.0, 1.0) -0.3 (-0.7 to 0.2) 
B. Ultrasound Synovitis/ 
Erosions 
Oligoarticular PsA 
without dactylitis [75/99 
(75.8%)] 
Oligoarticular PsA with 
dactylitis [24/99 
(24.2%)] 
Difference/ p value 
Total GS≥2 464/2934 (15.8%) 130/824 (15.8%) p=0.98 
Total PD≥1 81/2934 (2.8%) 22/824 (2.7%) p=0.61 
Total GS≥2+PD>1 67/2934 (2.3%) 19/824 (2.3%) p=0.86 
Total US erosions 13/2748 (0.5%) 3/771 (0.4%) p=0.76 
Total erosion score (patient level) Mean 0.29 (SD 0.91)  
Median 0 (0,0) 
Mean 0.20 (SD 0.40) 
Median 0 (0,0) 
p=0.67 
Total patients US erosive 9/75 (12.0%) 3/24(12.5%) p=0.59 




(75.8%)] (same as 
above (B))  




Difference/ p value  
Total GS≥2 464/2934 (15.8%) 117/784 (14.9%) p=0.54 
Total PD≥1 81/2934 (2.8%) 17/784 (2.2%) p=0.36 
Total GS≥2+PD>1 67/2934 (2.3%) 14/784 (1.8%) p=0.66 
Total US erosions 13/2748 (0.5%) 2/735 (0.3%) p=0.46 
Total erosion score (patient level) Mean 0.29 (SD 0.91)  
Median 0 (0,0) 
Mean 0.13 (SD 0.45), 
Median 0 (0,0) 
p=0.387 
Total patients US erosive 9/75 (12.0%) 2/24 (8.33%) p=0.472 
*p<0.05, **p<0.01, ***p<0.001. 
BMI: Body mass index; DLQI: Dermatology quality of life index; HAQ: Health assessment questionnaire disability 
index; MASES: Maastricht ankylosing spondylitis enthesitis scores; mNAPSI: Modified nail psoriasis severity index; 
PASI: Psoriasis area severity index; PsAQoL: PsA quality of life. 
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S2 b) Polyarticular subset 
 





Polyarticular PsA with 
dactylitis [53/66 
(80.3%)] 
Difference/ p value 
Clinical 
Age, mean (SD), years 48.8 (14.4) 44.2 (14.5) 4.6 (-4.3 to 13.5) 
Male 6 (46%) 30 (57%) p=0.5 
Symptom duration, median (IQR), 
months 
18.0 (12.0, 36.0) 12.0 (6.0, 24.0) -6.0 (-18.3 to 6.3) 
Duration from diagnosis, median 
(IQR), months 
2.3 (0.0, 2.8) 1.3 (0.5, 5.2) -1.1 (-3.4 to 1.8) 
Early morning stiffness median 
(IQR), minutes 
120.0 (60.0, 180.0) 90.0 (40.0, 240.0) -30 (-148.5 to 88.5) 
TJC (78), median (IQR) 10.0 (7.0, 16.0) 12.0 (7.0, 21.0) 2.0 (-6.4 to 10.4) 
SJC (76), median (IQR) 7.0 (5.0, 10.0) 10.0 (7.0, 14.0) 3.0 (-1.2 to 7.2) 
TJC (78) median (IQR) (excluding 
dactylitis) 
10.0 (7.0-16-0) 6.0 (4.0-13.0) -4.0 (-9.8 to 1.8) 
SJC (76) median (IQR) (excluding 
dactylitis) 
7.0 (5.0-10.0) 5.0 (3.0-8.0) -2.0 (-5.2 to 1.2) 
Current Psoriasis 13/13 (100.0%) 49/53 (92.5%) p=0.307 
Family history of Psoriasis 10 (77%) 31 (60%) p=0.25 
PASI, median (IQR) 2.8 (1.4, 5.2) 2.8 (0.4, 4.2) 0 (-2.4 to 2.4) 
Psoriatic Nail dystrophy 6 (46%) 27 (51%) p=0.76 
mNAPSI, median (IQR) 0.0 (0.0, 3.0) 1.0 (0.0, 10.0) 1 (-4.5 to 6.5) 
Clinical Enthesitis 3 (23%) 27 (51%) p=0.071 
MASES, median (IQR) 0.0 (0.0, 0.0) 1.0 (0.0, 2.0) 1.0 (-0.03 to 2.1) 
BMI, median (IQR) 28.6 (24.6, 31.4) 29.4 (26.2, 31.7) 0.3 (-1.7 to 2.4) 
Smoking (current) 2 (15%) 4 (8%) p=0.39 
Disease phenotype 
Predominant DIP joint disease 2 (15%) 10 (20%) p=0.68 
Axial disease 1 (8%) 7 (14%) p=0.54 
Arthritis Mutilans 0 0 0 
Laboratory markers 
CRP (mg/L), median (IQR) 5.0 (5.0, 16.5) 12.5 (5.0, 23.0) 7.5 (-3.3 to 18.3) 
Elevated (>10) 5 (38%) 28 (53%) p=0.35 
ESR, median (IQR) 12.0 (6.0, 27.0) 24.0 (10.0, 36.0) 12 (-4.1 to 28.1) 
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Polyarticular PsA with 
dactylitis [53/66 
(80.3%)] 
Difference/ p value 
Patient Reported Outcomes (PROs) 
PsAQoL, median (IQR) 7.0 (1.0, 12.0) 8.0 (3.5, 13.5) 1.0 (-6.3 to 8.3) 
DLQI, median (IQR) 4.0 (1.0, 17.0) 2.0 (1.0, 6.0) -2.0 (-6.8 to 2.8) 
HAQ, median (IQR) 0.9 (0.2, 1.2) 0.9 (0.5, 1.4) 0.125 (-0.5 to 0.8) 
B. Ultrasound Synovitis/ 
Erosions 
Polyarticular PsA 
without dactylitis [11/56 
(19.6%)] 
Polyarticular PsA with 
dactylitis [45/56 
80.4%)] 
Difference/ p value 
Total GS≥2 87/488 (17.8%) 512/1897 (27.0%) p<0.001** 
Total PD≥1 33/488 (6.8%) 176/1897 (9.3%) p<0.001** 
Total GS≥2+PD>1 22/488 (4.51%) 152/1897 (8.0%) p<0.001** 
Total US erosions 2/458 (0.44%) 30/1786 (1.7%) p=0.04* 
Total erosion score (patient level) Mean 0.18 (SD 0.40) 
Median 0 (0,0) 
Mean 1 (SD 1.93), 
Median 0 (0,1) 
p=0.17 
Total patients US erosive 2/11 (18.2%) 17/45 (37.7%) p=0.19 




(19.6%)] (same as 
above (B)) 




Difference/ p value  
Total GS≥2 87/488 (17.8%) 390/1682 (23.2%) p=0.01* 
Total PD≥1 33/488 (6.8%) 109/1682 (6.5%) p=0.825 
Total GS≥2+PD>1 22/488 (4.5%) 87/1682 (5.2%) p=0.036* 
Total US erosions 2/458 (0.44%) 23/1580 (1.46%) p=0.08 
Total erosion score (patient level) Mean 0.18 (SD 0.40) 
Median 0 (0,0) 
Mean 0.76 (SD 1.79) 
Median 0 (0,1) 
p=0.3 
Total patients US erosive 2/11 (18.2%) 15/45 (33.3%) p=0.277 
*p<0.05, **p<0.01, ***p<0.001. 
BMI: Body mass index; DLQI: Dermatology quality of life index; HAQ: Health assessment questionnaire disability 
index; MASES: Maastricht ankylosing spondylitis enthesitis scores; mNAPSI: Modified nail psoriasis severity index; 
PASI: Psoriasis area severity index; PsAQoL: PsA quality of life. 
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Supplementary tables S3 a) Oligoarticular, b) Polyarticular:  Subgroup 
analyses stratified by phenotype (polyarticular defined as tender and/or swollen joints 
³5) for clinical characteristics (A), ultrasound synovitis and erosion outcomes with 
dactylitis digits included and excluded (B and C respectively) for dactylitic versus non-
dactylitic PsA.  
 
S3 a) Oligoarticular subset 
 








Difference/ p value 
Clinical 
Age, mean (SD), years 43.6 (12.5) 41.0 (11.8) 2.7 (-3.1 to 8.4) 
Male 16 (33%) 12 (41%) p=0.48 
Symptom duration, median (IQR), 
months 15.5 (9.5, 30.0) 12.0 (6.0, 24.0) -6 (-14.9 to 2.9) 
Duration from diagnosis, median 
(IQR), months 1.5 (0.0, 2.8) 1.2 (0.0, 4.6) -0.3 (-1.9 to 1.3) 
Early morning stiffness median 
(IQR), minutes 30.0 (6.5, 60.0) 60.0 (10.0, 120.0) 30 (-7.2 to 67.2) 
TJC (78), median (IQR) 3.0 (1.0, 5.5) 6.0 (3.0, 9.0) 3.0 (0.6 to 5.4)* 
SJC (76), median (IQR) 1.0 (0.0, 2.0) 4.0 (2.0, 6.0) 3.0 (1.6 to 4.4)*** 
TJC (78) median (IQR) (excluding 
dactylitis) 3.0 (1.0, 5.5) 
3.0 (1.0, 6.0) 0.0 (-2.7 to 2.7) 
SJC (76) median (IQR) (excluding 
dactylitis) 1.0 (0.0, 2.0) 
1.0 (0.0, 2.0) 0.0 (-1.0 to 1.0) 
Current Psoriasis 48 (100%) 29 (100%) - 
Family history of Psoriasis 25 (54%) 18 (64%) p=0.40 
PASI, median (IQR) 2.5 (0.6, 4.8) 1.8 (0.4, 4.0) -0.9 (-2.8 to 1.0) 
Psoriatic Nail dystrophy 27 (56%) 11 (38%) p=0.12 
mNAPSI, median (IQR) 2.0 (0.0, 5.0) 0.0 (0.0, 4.0) -2.0 (-4.4 to 0.4) 
Clinical Enthesitis 17 (35%) 13 (45%) p=0.41 
MASES, median (IQR) 0.0 (0.0, 2.5) 0.0 (0.0, 2.0) 0 (-0.7 to 0.7) 
BMI, median (IQR) 26.8 (23.5, 30.8) 27.7 (23.8, 31.6) 0.9 (-2.0 to 3.8) 
Smoking (current) 9 (19%) 5 (17%) p=0.63 
Disease phenotype 
Predominant DIP joint disease 3 (7%) 2 (7%) p=0.90 
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Difference/ p value 
Axial disease 1 (2%) 3 (11%) p=0.12 
Arthritis Mutilans 0 0 0 
Laboratory markers 
CRP (mg/L), median (IQR) 5.0 (5.0, 8.2) 5.0 (5.0, 14.9) 0 (-2.5 to 2.5) 
Elevated (>10) 9 (19%) 11 (38%) p=0.063 
ESR, median (IQR) 10.5 (5.0, 23.0) 21.0 (5.0, 27.0) 10.0 (0.3 to 19.7)* 
Patient Reported Outcomes (PROs) 
PsAQoL, median (IQR) 4.0 (0.0, 12.0) 3.5 (1.0, 10.0) 0 (-5.7 to 5.7) 
DLQI, median (IQR) 3.0 (1.0, 6.0) 3.5 (1.0, 7.0) 1.0 (-1.8 to 3.8) 
HAQ, median (IQR) 0.3 (0.0, 1.4) 0.4 (0.0, 1.0) 0.97 
B. Ultrasound Synovitis/ 
Erosions 
Oligoarticular PsA 
without dactylitis [44/69 
(63.7%)] 
Oligoarticular PsA with 
dactylitis [25/69 
(36.2%)] 
Difference/ p value 
Total GS≥2 308/1951 (15.8%) 211/1026 (20.6%) p=0.001** 
Total PD≥1 53/1951 (2.7%) 47/1026 (4.6%) p=0.007** 
Total GS≥2+PD>1 46/1951 (2.4%) 41/1026 (4.0%) p=0.012* 
Total US erosions 9/1833 (0.5%) 9/968 (0.9%) p=0.167 
Total erosion score (patient level) Mean 0.32 (SD 1.0) 
Median 0 (0,0) 
Mean 0.64 (SD 1.3) 
Median 0 (0,0) 
p=0.048* 
Total patients US erosive 5/44 (11.4%) 6/25 (24.0%) p=0.17 
C. Ultrasound Synovitis/ 
Erosions 
Oligoarticular PsA 
without dactylitis [44/69 
(63.7%)] (same as 
above (B)) 




Difference/ p value 
Total GS≥2 308/1951 (15.8%) 184/1966 (19.1%) p=0.027* 
Total PD≥1 53/1951 (2.7%) 33/966 (3.4%) p=0.291 
Total GS≥2+PD>1 46/1951 (2.4%) 28/966 (2.9%) p=0.084 
Total US erosions 9/1833 (0.5%) 5/912 (0.6%) p=0.84 
Total erosion score (patient level) Mean 0.31 (SD 1.0) 
Median 0 (0,0) 
Mean 0.32 (SD 1.0) 
Median 0 (0,0) 
p=0.99 
Total patients US erosive 5/44 (11.4%) 4/25 (16.0%) p=0.71 
*p<0.05, **p<0.01, ***p<0.001. 
BMI: Body mass index; DLQI: Dermatology quality of life index; HAQ: Health assessment questionnaire disability 
index; MASES: Maastricht ankylosing spondylitis enthesitis scores; mNAPSI: Modified nail psoriasis severity index; 
PASI: Psoriasis area severity index; PsAQoL: PsA quality of life. 
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S3 b) Polyarticular subset 
 





Polyarticular PsA with 
dactylitis 
[52/100(52.0%)] 
Difference/ p value 
Clinical 
Age, mean (SD), years 45.2 (13.1) 45.3 (13.9) -0.1 (-5.5 to 5.3) 
Male 22 (46%) 30 (58%) p=0.24 
Symptom duration, median (IQR), 
months 18.0 (11.0, 48.0) 12.0 (6.0, 24.0) -6 (-15.7 to 3.7) 
Duration from diagnosis, median 
(IQR), months 0.5 (0.0, 2.7) 1.2 (0.5, 4.6) 0.7 (-0.4 to 1.8) 
Early morning stiffness median 
(IQR), minutes 60.0 (30.0, 120.0) 75.0 (35.0, 240.0) 30 (-20.0 to 80.1) 
TJC (78), median (IQR) 8.5 (4.0, 14.5) 12.5 (6.0, 23.5) 4.0 (-1.7 to 9.7) 
SJC (76), median (IQR) 2.0 (0.0, 4.5) 7.5 (6.0, 14.0) 6.0 (3.6 to 8.4)*** 
TJC (78) median (IQR) (excluding 
dactylitis) 
8.5 (4.0, 14.5) 6.0 (4.0-14.0) -3.0 (-7.5 to 1.5) 
SJC (76) median (IQR) (excluding 
dactylitis) 
2.0 (0.0, 4.5) 4.0 (1.0-7.0) 2.0 (-0.1 to 4.1) 
Current Psoriasis 48 (100.0%) 45 (86.5%) p=0.008** 
Family history of Psoriasis 27 (56%) 31 (62%) p=0.56 
PASI, median (IQR) 3.0 (1.2, 5.2) 1.9 (0.0, 4.0) -1.1 (-2.7 to 0.5) 
Psoriatic Nail dystrophy 25 (52%) 29 (56%) p=0.71 
mNAPSI, median (IQR) 1.5 (0.0, 9.0) 2.5 (0.0, 10.0) 1 (-2.8 to 4.8) 
Clinical Enthesitis 19 (40%) 29 (56%) p=0.11 
MASES, median (IQR) 0.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.1 to 1.9)* 
BMI, median (IQR) 29.6 (25.9, 33.2) 29.4 (25.1, 31.3) -0.4 (-2.7 to 2.0) 
Smoking (current) 10 (21%) 4 (8%) p=0.16 
Disease phenotype 
Predominant DIP joint disease 4 (8%) 11 (22%) p=0.060 
Axial disease 16 (33%) 6 (12%) p=0.011* 
Arthritis Mutilans 0 0 0 
Laboratory markers 
CRP (mg/L), median (IQR) 5.0 (5.0, 12.0) 9.6 (5.0, 20.5) 4.6 (-0.4 to 9.6) 
Elevated (>10) 15 (31%) 25 (48%) p=0.086 
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Polyarticular PsA with 
dactylitis 
[52/100(52.0%)] 
Difference/ p value 
ESR, median (IQR) 15.5 (7.0, 41.0) 20.0 (9.0, 36.0) 3.0 (-8.8 to 14.8) 
Patient Reported Outcomes (PROs) 
PsAQoL, median (IQR) 7.0 (1.0, 13.0) 8.0 (3.0, 13.0) 1.0 (-3.4 to 5.4) 
DLQI, median (IQR) 5.0 (1.0, 12.0) 2.0 (1.0, 5.0) -3.0 (-6.4 to 0.4) 
HAQ, median (IQR) 0.8 (0.4, 1.4) 0.9 (0.5, 1.5) 0.1 (-0.3 to 0. 
B. Ultrasound Synovitis/ 
Erosions 
Polyarticular PsA 
without dactylitis [42/86 
(48.8%)] 
Polyarticular PsA with 
dactylitis [44/86 
51.1%)] 
Difference/ p value 
Total GS≥2 243/1471 (16.5%) 431/1695 (25.4%) p<0.001*** 
Total PD≥1 61/1471 (4.2%) 151/1695 (8.9%) p<0.001*** 
Total GS≥2+PD>1 43/1471 (2.9%) 130/1695 (7.7%) p<0.001** 
Total US erosions 6/1373 (0.4%) 24/1589 (1.5%) p=0.004** 
Total erosion score (patient level) Mean 0.23 (SD 0.69) 
Median 0 (0,0) 
Mean 0.77 (SD 1.77) 
Median 0 (0,1) 
p=0.07* 
Total patients US erosive 6/42 (14.3%) 14/44 (31.8%) p=0.04* 




(48.8%)] (same as 
above (B)) 




Difference/ p value 
Total GS≥2 243/1471 (16.5%) 323/1500 (21.5%) p=0.001** 
Total PD≥1 61/1471 (4.2%) 93/1500 (6.2%) p=0.011* 
Total GS≥2+PD>1 43/1471 (2.9%) 73/1500 (4.9%) p=0.001** 
Total US erosions 6/1373 (0.4%) 20/1403 (1.4%) p=0.007** 
Total erosion score (patient level) Mean 0.23 (SD 0.69) 
Median 0 (0,0) 
Mean 0.65 (SD 1.7) 
Median 0 (0,1) 
p=0.14 
Total patients US erosive 6/42 (14.3%) 13/44 (29.6%) p=0.088 
*p<0.05, **p<0.01, ***p<0.001. 
BMI: Body mass index; DLQI: Dermatology quality of life index; HAQ: Health assessment questionnaire disability 
index; MASES: Maastricht ankylosing spondylitis enthesitis scores; mNAPSI: Modified nail psoriasis severity index; 
PASI: Psoriasis area severity index; PsAQoL: PsA quality of life. 
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Supplementary table S4 
 
Characteristics of the newly diagnosed, early PsA cohort dichotomised by non-





Dactylitic PsA (Past 





Age, mean (SD), years 44.0 (13.1) 44.2 (12.9) 0.91 
Male 35 (43%) 45 (47%) 0.63 
Symptom duration, median 
(IQR), months 13.0 (11.0, 36.0) 12.0 (6.0, 24.0) 0.100 
Duration from diagnosis, 
median (IQR), months 0.1 (0.0, 0.2) 0.1 (0.0, 0.3) 0.18 
Early morning stiffness 
median (IQR), minutes 30.0 (15.0, 60.0) 60.0 (17.5, 180.0) 0.001 
TJC (78), median (IQR) 4.0 (1.0, 10.0) 8.0 (3.5, 18.5) 0.001 
SJC (76), median (IQR) 1.0 (0.0, 3.0) 6.0 (2.0, 11.0) <0.001 
Current Psoriasis 81/81 (100%) 89/96 (92.6%) 0.013 
Family history of Psoriasis 
43 (54%) 58 (62%) 0.29 
PASI, median (IQR) 2.9 (0.9, 4.8) 1.9 (0.4, 4.2) 0.10 
Psoriatic Nail dystrophy 45 (56%) 47 (49%) 0.38 
mNAPSI, median (IQR) 2.0 (0.0, 7.0) 0.0 (0.0, 8.5) 0.84 
Clinical Enthesitis 29 (36%) 49 (51%) 0.042 
MASES, median (IQR) 0.0 (0.0, 2.0) 1.0 (0.0, 2.0) 0.20 
BMI, median (IQR) 27.6 (24.0, 31.9) 28.8 (25.1, 31.6) 0.60 
Smoking (current) 16 (20%) 12 (12%) 0.36 
Disease phenotype 
Oligoarthritis (defined by 
SJC<5) 70 (86%) 41 (43%) <0.001 
DIP joint disease 6 (8%) 14 (16%) 0.10 
Axial disease 15 (19%) 11 (12%) 0.24 
Arthritis Mutilans 0 0 0 
Laboratory markers 
CRP (mg/L), median (IQR) 5.0 (5.0, 8.2) 6.7 (5.0, 18.0) 0.001 
Elevated CRP (>10mg/L) 18 (22%) 42 (44%) 0.003 
ESR, median (IQR) 11.0 (6.0, 26.0) 21.0 (7.0, 36.0) 0.060 
Patient Reported Outcomes (PROs) 
PsAQoL, median (IQR) 6.0 (0.0, 12.0) 6.0 (1.0, 13.0) 0.47 
DLQI, median (IQR) 3.0 (1.0, 9.0) 2.0 (1.0, 6.0) 0.085 
HAQ, median (IQR) 0.6 (0.1, 1.2) 0.8 (0.4, 1.4) 0.21 





Total GS≥2 414/2786 (14.9%) 779/3357 (23.6%) p<0.001 
Total PD≥1 80/2786 (2.9%) 232/3357 (6.9%) p<0.001 
Total GS≥2+PD>1 61/2786 (2.2%) 199/3357 (6.3%) p<0.001 
Total US erosions 10/2606 (0.4%) 38/3157 (1.2%) p<0.001 
Total US erosive patients 9/71 (12.7%) 22/84 (26.2%) p=0.036 
BMI: Body mass index; DLQI: Dermatology quality of life index; HAQ: Health assessment questionnaire disability 
index; MASES: Maastricht ankylosing spondylitis enthesitis scores; mNAPSI: Modified nail psoriasis severity index; 
PASI: Psoriasis area severity index; PsAQoL: PsA quality of life. 
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Supplementary table S5 
Characteristics of the newly diagnosed, early PsA cohort dichotomised by dactylitis 





Dactylitic PsA (Past 





Age, mean (SD), years 43.4 (12.7) 43.4 (13.6) 1.00 
Male 23 (36%) 34 (50%) 0.10 
Symptom duration, median 
(IQR), months 12.0 (7.0, 18.0) 9.0 (6.0, 18.0) 0.38 
Duration from diagnosis, 
median (IQR), months 0.1 (0.0, 0.2) 0.1 (0.0, 0.4) 0.29 
Early morning stiffness 
median (IQR), minutes 30.0 (15.0, 105.0) 60.0 (15.0, 180.0) 0.033 
TJC (78), median (IQR) 4.0 (1.5, 9.0) 8.5 (4.5, 20.0) <0.001 
SJC (76), median (IQR) 1.0 (0.0, 3.0) 6.5 (2.5, 11.0) <0.001 
Current Psoriasis 64/64 (100%) 62/68 (91.2%) 0.02 
Family history of Psoriasis 
34 (55%) 43 (66%) 0.19 
PASI, median (IQR) 2.9 (1.1, 5.2) 1.9 (0.4, 3.9) 0.10 
Psoriatic Nail dystrophy 35 (55%) 33 (49%) 0.48 
mNAPSI, median (IQR) 1.5 (0.0, 6.0) 0.0 (0.0, 8.5) 1.00 
Clinical Enthesitis 24 (38%) 35 (51%) 0.11 
MASES, median (IQR) 0.0 (0.0, 2.0) 1.0 (0.0, 2.0) 0.33 
BMI, median (IQR) 27.8 (23.5, 31.4) 28.6 (25.0, 31.2) 0.61 
Smoking (current) 13 (20%) 8 (12%) 0.40 
Disease phenotype 
Oligoarthritis (defined by 
SJC<5) 56 (88%) 24 (35%) <0.001 
DIP joint disease 4 (7%) 11 (17%) 0.073 
Axial disease 11 (18%) 7 (11%) 0.25 
Arthritis Mutilans 0 0 0 
Laboratory markers 
CRP (mg/L), median (IQR) 5.0 (5.0, 9.1) 8.8 (5.0, 19.7) 0.009 
Elevated CRP (>10mg/L) 15 (23%) 32 (47%) 0.005 
ESR, median (IQR) 10.0 (5.0, 25.0) 21.5 (7.0, 36.0) 0.065 
Patient Reported Outcomes (PROs) 
PsAQoL, median (IQR) 7.0 (0.0, 12.0) 6.0 (1.0, 13.0) 0.87 
DLQI, median (IQR) 3.0 (1.0, 9.0) 2.0 (1.0, 6.0) 0.079 
HAQ, median (IQR) 0.6 (0.1, 1.3) 0.8 (0.2, 1.4) 0.34 





Total GS≥2 383/2218 (17.3%) 561/2373 (23.6%) p<0.001 
Total PD≥1 83/2218 (3.7%) 181/2373 (7.6%) p<0.001 
Total GS≥2+PD>1 66/2218 (3.0%) 157/2373 (6.6%) p<0.001 
Total US erosions 7/2075 (0.3%) 31/2233 (1.4%) p<0.001 
Total US erosive patients 7/55 (12.7%) 19/59 (32.2%) p=0.013 
BMI: Body mass index; DLQI: Dermatology quality of life index; HAQ: Health assessment questionnaire disability 
index; MASES: Maastricht ankylosing spondylitis enthesitis scores; mNAPSI: Modified nail psoriasis severity index; 
PASI: Psoriasis area severity index; PsAQoL: PsA quality of life. 
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